RA Capital Says Better Times Ahead For Healthcare, Biotech As Fund Drops 16% In H1

Halfway through 2016 – one year into the deepest drawdowns in the history of the biotech sector – a major healthcare and life sciences investment fund wants to explain its performance, rated as one of the best by one study.

RA Capital, down -16.4% year to date, says the political rhetoric will subside

After starting the year down more than -21%, but since recovering to down -16.4% as of the end of June, RA Capital Healthcare Fund says mean reversion could be upon us. The drawdown – and the political reaction against healthcare in the wake of Martin Shkreli and Valeant Pharmaceutical scandals –...